• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

Mitsubishi Tanabe Pharma

Alsitek: New Drug for ALS
Posted inClinical Trials, Neuroscience, Rare/Orphan Diseases

Alsitek: New Drug for ALS

June 17, 2022September 8, 2022

Oral masitinib doubles the life in patients with amyotrophic lateral sclerosis.

Covifenz: Medicago’s Plant-Derived COVID-19 Vaccine
Posted inCOVID-19, Infections, New Drugs, Regulatory

Covifenz: Medicago’s Plant-Derived COVID-19 Vaccine

June 5, 2022September 8, 2022

Innovative Medicago’s vaccine is made by molecular pharming technology.

Ponvory: Another Drug for Multiple Sclerosis
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Ponvory: Another Drug for Multiple Sclerosis

May 17, 2021September 8, 2022

Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News